New method to measure liver stiffness with FibroScan

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, interventional, multicenter investigation at two French sites enrolling 114 adults to develop a new liver stiffness measurement method using a Research FibroScan device. Participants followed in hepatology or endocrinology clinics who can give written consent and are affiliated with the French social security system will undergo FibroScan examinations and related data collection. Vulnerable patients and those with ascites or heart failure are excluded. Collected measurements will be used to refine and validate the new measurement approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (≥ 18 years of age) followed in the hepatology or endocrinology department for liver disease, suspected liver disease or consequences of liver disease, all etiologies combined.
* Adult patient able to give his written consent
* Patient affiliated to the French Social Security system

Exclusion Criteria:

* Vulnerable patients
* Patients with liver ascites
* Patients with heart failure

Where it's running

• Groupe Hospitalier Nord Essonne - Site Paris- Saclay
  Orsay, France Recruiting
• Hôpital Pitié-Salpêtrière
  Paris, Île-de-France Region, France Recruiting

Study contacts

• Study coordinator: Anne Llorca
• Email: anne.llorca@echosens.com
• Phone: +33144827850

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Everolimus-based calcineurin-free immunosuppression one year after liver transplant

  This trial tests whether switching to or using everolimus with reduced calcineurin inhibitors after year one post-liver transplant can protect kidney function while maintaining graft health in adults at low rejection risk.

  Recruiting Phase 3 Hannover Medical School · Heidelberg, Baden-Wurttemberg and 15 other locations · NCT07739914

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• Safety and how the drug behaves in adults with moderate to severe liver impairment

  This study tests the safety and how INCB123667 moves through the body when taken by adults with moderate to severe liver impairment.

  Recruiting at 4 sites Phase 1 Incyte Corporation · Chandler, Arizona and 3 other locations · NCT07559474

• Single-probe FibroScan for measuring liver stiffness

  This project will try a single-probe FibroScan to measure liver stiffness in adults with chronic liver disease and compare its results to the standard M and XL probes.

  Recruiting Echosens · Besançon and 3 other locations · NCT07400289

• Using polyene phosphatidylcholine to protect the liver after hepatectomy

  This test checks whether giving polyene phosphatidylcholine before surgery plus magnesium isoglycyrrhizinate after surgery better prevents liver injury in people having laparoscopic liver resection for hepatocellular carcinoma.

  Recruiting Phase 4 Anhui Provincial Hospital · Hefei, Anhui · NCT07150624

• CRISPR-edited donor liver transplant to reduce rejection

  This trial will try transplanting deceased-donor livers that have had key HLA genes removed with CRISPR to see if they cause less rejection in adults needing a liver transplant.

  Recruiting Phase 1/2 American Organ Transplant and Cancer Research Institute LLC · Beijing, Changping · NCT07053488

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.